Activities of doripenem (S-4661) against drug-resistant clinical pathogens

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 8, 2004, Pages 3136-3140

  Jones, Ronald N ^a,b   Huynh, Holly K ^a   Biedenbach, Douglas J ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; ERTAPENEM; IMIPENEM; LINEZOLID; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; DOSE TIME EFFECT RELATION; DRUG STABILITY; ENTEROBACTERIACEAE; ENZYME BINDING; FERMENTATION INHIBITION; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; STREPTOCOCCUS;

BACTERIA; BACTERIAL INFECTIONS; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; GRAM-NEGATIVE BACTERIA; HUMANS; PHENOTYPE;

EID: 3342910269     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.8.3136-3140.2004     Document Type: Article

References (17)

1. Bonfiglio, G., G. Russo, and G. Nicoletti. 2002. Recent developments in carbapenems. Expert Opin. Investig. Drugs 11:529-544.
2. Gales, A. C., D. J. Biedenbach, P. Winokur, D. M. Hacek, M. A. Pfaller, and R. N. Jones. 2001. Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: results from the MYSTIC programme. Diagn. Microbiol. Infect. Dis. 39:125-127.
3. Ge, Y., M. A. Wikler, D. F. Sahm, R. S. Blosser-Middleton, and J. A. Karlowsky. 2004. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob. Agents Chemother. 48:1384-1396.
4. Iso, Y., T. Irie, Y. Nishino, K. Motokawa, and Y. Nishitani. 1996. A novel β-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrroldin-3-ylthio)- 1β-methylcarbapenems. J. Antibiot. 49:199-209.
5. Jones, R. N. 2001. In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains. J. Chemother. 13:363-376.
6. Jones, R. N. 2003. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY antimicrobial surveillance program (1997-2001). Semin. Respir. Crit. Care Med. 24:121-133.
7. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worse nightmare? Clin. Infect. Dis. 34:634-644.
8. Masuda, N., E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino. 2000. Substrate specificities of MexAB-OprM, Mex(B)-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:3322-3327.
9. Mikamo, H., K. Izumi, Y.-X. Hua, Y. Hayasaki, Y. Sato, and T. Tamaya. 2000. In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens. J. Antimicrob. Chemother. 46:471-474.
10. Mori, M., M. Hikida, T. Nishihara, T. Nasu, and S. Mitsuhashi. 1996. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I. J. Antimicrob. Chemother. 37:1034-1036.
11. Mushtaq, S., Y. Ge, and D. M. Livermore. 2004. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob. Agents Chemother. 48:1313-1319.
12. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 6th ed. Document M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
13. National Committee for Clinical Laboratory Standards. 2004. Performance standards for antimicrobial susceptibility testing, 14th information supplement. Document M100-S13. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. Nomura, S., and A. Nagayama. 2002. In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections. J. Chemother. 14:155-160.
15. Tsuji, M., Y. Ishii, A. Ohno, S. Miyazaki, and K. Yamaguchi. 1998. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob. Agents Chemother. 42:184-187.
16. Watanabe, A., H. Takahashi, T. Kikuchi, T. Kobayashi, K. Gomi, S. Fujimura, Y. Tokue, and T. Nukiwa. 2000. Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens. Chemotherapy 46:184-187.
17. Wiseman, L. R., A. J. Wagstaff, R. N. Brogden, and H. M. Bryson. 1995. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 50:73-101.